Brief: Actinium Pharmaceuticals Announces Actimab-A Intellectual Property And Manufacturing Advances And Provides NYSE American Listing Update
14/08/2026 22:34
BRIEF-Actinium Pharmaceuticals Announces Actimab-A Intellectual Property And Manufacturing Advances And Provides NYSE American Listing Update Aug 14 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A:
ACTINIUM PHARMACEUTICALS ANNOUNCES ACTIMAB-A INTELLECTUAL PROPERTY AND MANUFACTURING ADVANCES AND PROVIDES NYSE AMERICAN LISTING UPDATE
ACTINIUM PHARMACEUTICALS - AMENDS IND TO ADD MANUFACTURER FOR CRADA AND COMPANY STUDIES; MILESTONES EXPECTED H2 2026-2027
Source text: ID:nPn95MsFRa
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals Announces Actimab-A Intellectual Property And Manufacturing Advances And Provides NYSE American Listing Update
Brief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225